nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.10.2004 | Review Article

Pimozide in Dermatologic Practice

A Comprehensive Review

verfasst von: Dr Cynthia R. Lorenzo, John Koo

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2004

Einloggen, um Zugang zu erhalten

Abstract

Pimozide is an antipsychotic drug of the diphenylbutylpiperidine class. In the US, it is FDA-approved only as a backup treatment for Gilles de la Tourette syndrome, although it has been used in other countries for many years as a treatment for schizophrenia. In the past 20 years, pimozide has been found to be especially efficacious in the treatment of monosymptomatic hypochondriacal psychoses and is used by psychiatrists and dermatologists for this off-label purpose. In particular, pimozide is considered the treatment of choice for delusions of parasitosis. In addition, pimozide has been found to be efficacious in the treatment of body dysmorphic disorder, metastatic melanoma, trichotillomania, and trigeminal and postherpetic neuralgia. This review aims to familiarize physicians, especially dermatologists, on the uses of pimozide in dermatologic practice. A review of the literature was performed and the relevant information synthesized to give a complete overview of the drug and its therapeutic uses in dermatology.

Janssen PAJ, Brugmans J, Dony J, et al. An international double-blind clinical evaluation of pimozide. J Clin Pharmacol 1972; 12: 26–34

Janssen PAJ, Niemegeers CJE, Schellekens KHL, et al. Pimozide: a chemically novel, highly potent and orally acting neuroleptic drug. Arzneimittel Forschung 1968; 18: 261–87PubMed

Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin 2001; 19: 179–97PubMed

Opler LA, Feinberg SS. The role of pimozide in clinical psychiatry: a review. J Clin Psychiatry 1991; 52: 221–33PubMed

Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl. 10: 5–14PubMed

Gould R, Murphy K, Reynolds I, et al. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A 1983; 80: 5122–5PubMedCrossRef

Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988; 33: 149–60PubMedCrossRef

Creese I, Feinberg AP, Snyder SH. Butyrophenone influences on the opiate receptor. Eur J Pharmacol 1976; 36: 231–5PubMedCrossRef

Cohen ML, Carpenter R, Schenck K, et al. Effect of nitrendipine, diltiazem, trifluoperazine and pimozide on serotonin2 (5-HT2) receptor activation in the rat uterus and jugular vein. J Pharmacol Exper Therap 1986; 238: 860–7

10.

Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996; 124: 35–9PubMedCrossRef

11.

Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27–38PubMed

12.

Driscoll MS, Rothe MJ, Grant-Kels JM, et al. Delusional parasitosis: a dermatologic, psychiatric and pharmacologic approach. J Am Acad Dermatol 1993; 29: 1023–33PubMedCrossRef

13.

Pinder R, Brogden P, Sawyer P, et al. Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 1976; 12: 1–40PubMedCrossRef

14.

The Scottish Schizophrenic Research Group. The Scottish first episode schizophrenia study: II. Treatment: pimozide versus flupenthixol. Br J Psychiatry 1987; 150: 334–8CrossRef

15.

Koo J, Lee CS. Delusions of parasitosis; a dermatologist’s guide to diagnosis and treatment. Am J Clin Dermatol 2001; 2: 285–90PubMedCrossRef

16.

Lindskov R, Baadsgaard O. Delusions of infestation treated with pimozide. Acta Derm Venereol 1985; 65: 267–70PubMed

17.

Chouinard G, Lehmann HE, Ban TA. Pimozide in the treatment of chronic schizophrenic patients. Curr Ther Res 1970; 12: 598–603PubMed

18.

Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 1987; 144: 673–5PubMed

19.

Shapiro AK, Shapiro E, Fulop G. Pimozide treatment of tic and Tourette disorders. Pediatrics 1987; 79: 1032–9PubMed

20.

Tueth MJ, Cheong JA. Clinical uses of pimozide. South Med J 1993; 86: 344–9PubMedCrossRef

21.

Shopsin B, Selzer G. High-dose pimozide in acutely ill, newly admitted schizophrenic inpatients. Curr Ther Res 1977; 21: 755–67

22.

Shatzberg AF, Cole JO, Degattista C. Manual of clinical psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Association, 1997: 154–155

23.

Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82PubMedCrossRef

24.

Task force on DSM-IV. Diagnostic and statistical manual of mental disorders: text revision. 4th ed. Washington, DC: American Psychiatric Association, 2000

25.

Phillips KA. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach. CNS Spectr 2002; 7: 453–63PubMed

26.

Phillips KA. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull 1996; 32: 597–605PubMed

27.

Hamann K, Avnstrop C. Delusions of infestation treated by pimozide: a double blind crossover clinical study. Acta Derm Venereol 1982; 62: 55–8PubMed

28.

Ungvari G, Vladar K. Pimozide treatment for delusion of infestation. Act Nerv Super (Praha) 1986; 28: 103–7

29.

Munro A, Mok H. An overview of treatment in paranoia/delusional disorder. Can J Psychiatry 1995; 40: 616–22PubMed

30.

Reilly T, Batchelor D. The presentation and treatment of delusional parasitosis: a dermatological perspective. Int Clin Psychopharmacol 1986; 1: 340–53PubMedCrossRef

31.

Johnson GC, Anton RF. Pimozide in delusions of parasitosis [letter]. J Clin Psychiatry 1983; 44: 233PubMed

32.

Munro A. Monosymptomatic hypochondriacal psychosis manifesting as delusions of parasitosis. Arch Dermatol 1978; 114: 940–3PubMedCrossRef

33.

Riding J, Munro A. Pimozide in the treatment of monosymptomatic hypochondriacal psychosis. Acta Psychiatr Scand 1975; 52: 23–30PubMedCrossRef

34.

Zanol K, Slaughter J, Hall R. An approach to the treatment of psychogenic parasitosis. Int J Dermatol 1998; 37: 56–63PubMedCrossRef

35.

Damiani JT, Flowers FP, Pierce DK. Pimozide in delusions of parasitosis. J Am Acad Dermatol 1990; 22: 312–3PubMedCrossRef

36.

Lyell A. Delusions of parasitosis. Br J Dermatol 1983; 108: 485–99PubMedCrossRef

37.

Sheppard N, O’Loughlin S, Malone J. Psychogenic skin disease: a review of 35 cases. Br J Psychiatry 1986; 149: 636–43PubMedCrossRef

38.

Zomer SF, De Wit RF, Van Bonswijk JE, et al. Delusions of parasitosis: a psychiatric disorder to be treated by dermatologists?. An analysis of 33 patients. Br J Dermatol 1998; 138: 1030–2PubMedCrossRef

39.

Koo J, Gambla C. Delusions of parasitosis and other forms of monosymptomatic hypochondriacal psychosis. Dermatol Clin 1996; 14: 429–38PubMedCrossRef

40.

Elmer KB, George RM, Peterson K. Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol 2000; 43: 683–6PubMedCrossRef

41.

De Leon OA, Furmaga KM, Canterbury AL, et al. Risperidone in the treatment of delusions of infestation. Int J Psychiatry Med 1997; 27: 403–9PubMedCrossRef

42.

Moretti M. Psychosomatic dermatologic symptoms (Hungarian). Orv Hetil 2000; 141: 169–72PubMed

43.

Freyne A. Delusions of infestation: a case report of response to risperidone. Ir Med J 1999; 92: 435PubMed

44.

Gallucci G. Risperidone and the treatment of delusions of parasitosis in an elderly patient. Psychosomatics 1995; 36: 578–80PubMedCrossRef

45.

Cetin M, Agargun MY, Yigit S. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 1999; 60: 554PubMedCrossRef

46.

Safer DL, Roth WT. Risperidone in the treatment of delusional parasitosis: a case report. J Clin Psychopharmacol 1997; 17: 131–2PubMedCrossRef

47.

Weintraub E. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry 2000; 12: 247–9PubMed

48.

Fawcett RG. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis [letter]. Clin Psychiatry 2002; 63: 169CrossRef

49.

Yorston G. Treatment of delusional parasitosis with sertindole. Int J Geriatr Psychiatry 1997; 12: 1127–8PubMedCrossRef

50.

Hopkinson G. The psychiatric syndrome of infestation. Psychiatr Clin 1973; 6: 330–45

51.

King BH. Hypothesis: involvement of the serotonergic system in the clinical expression of monosymptomatic hypochondriasis. Pharmacopsychiatry 1990; 23: 85–9PubMedCrossRef

52.

Botschev C, Müller N. Opiate receptor antagonist for delusions of parasitosis. Biol Psychiatry 1991; 30: 530–1PubMedCrossRef

53.

Fernandez A. Pimozide in delusional dysmorphosis. Can J Psychiatry 1988; 33: 425–6PubMed

54.

Dorian BJ. Monosymptomatic hypochondriacal psychosis [letter]. Can J Psychiatry 1979; 24: 377

55.

Pollock BG. Successful treatment of pathological jealousy with pimozide. Can J Psychiatry 1982; 27: 86–7PubMed

56.

Munro A. Excellent response of pathological jealousy with pimozide. CMAJ 1984; 131: 852–3

57.

Byrne A, Yatham LN. Pimozide in pathological jealousy. Br J Psychiatry 1989; 155: 249–51PubMedCrossRef

58.

Lane RD. Successful fluoxetine treatment of pathologic jealousy. J Clin Psychiatry 1990; 51: 345–6PubMed

59.

Stein DJ, Hollander E, Josephson SC. Serotonin reuptake blockers for the treatment of obsessional jealousy. J Clin Psychiatry 1994; 55: 30–3PubMed

60.

Munro A, O’Brian JV, Ross D. Two cases of “pure” or “primary” erotomania successfully treated with pimozide. Can J Psychiatry 1985; 30: 619–22PubMed

61.

Costanza ME, Nathanson L, Schoenfeld D, et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 1977; 40: 1010–5PubMedCrossRef

62.

Rigel DS, Murray T, Bolden S, et al. Malignant melanoma: prevention, early detection and treatment in the 21st Century. CA Cancer J Clin 2000; 50: 215–30PubMedCrossRef

63.

Cohen GL, Falkson CI. Current treatment options for malignant melanoma. Drugs 1998; 55: 791–9PubMedCrossRef

64.

Wick MM, Byers L, Frei E. L-Dopa: selective toxicity for melanoma cells in vitro. Science 1977; 197: 468–9PubMedCrossRef

65.

Wick MM, Byers L, Frei E. Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J Invest Dermatol 1978; 71: 163–4PubMed

66.

Wick MM, Byers L, Frei E. Therapeutic effect of dopamine infusion on human malignant melanoma. Cancer Treat Rep 1982; 66: 1657–9PubMed

67.

Taub RN, Baker MA. Treatment of metastatic malignant melanoma with pimozide. Lancet 1979; I: 605CrossRef

68.

Neifeld JP, Tormey DC, Baker MA, et al. Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients. Cancer Treat Rep 1983; 67: 155–7PubMed

69.

Krummel TM, Neifeld JP, Taub RN. Effects of dopamine agonists and antagonists on murine melanoma. Cancer 1982; 49: 1178–84PubMedCrossRef

70.

Stein DJ, Hollander E. Low dose augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992; 53: 123–6PubMed

71.

Delzell JEJ, Grelle AR. Trigeminal neuralgia: new treatment options for a well-known cause of facial pain. Arch Fam Med 1999; 8: 264–8PubMedCrossRef

72.

Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989; 46: 960–3PubMedCrossRef

73.

Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18: 22–7PubMedCrossRef

74.

Duke EE. Clinical experience with pimozide: emphasis on its use in postherpetic neuralgia. J Am Acad Dermatol 1983; 8: 845–50PubMedCrossRef

Titel: Pimozide in Dermatologic Practice
A Comprehensive Review
verfasst von: Dr Cynthia R. Lorenzo
John Koo
Publikationsdatum: 01.10.2004
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 5/2004
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200405050-00007

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pimozide in Dermatologic Practice

A Comprehensive Review

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2004

Poly-L-Lactic Acid

Management of Cutaneous Warts

Management of Bullous Pemphigoid

Cosmetic Allergy

Sympathomimetic Drug Allergy

Localized Panniculitis and Subsequent Lipoatrophy with Subcutaneous Glatiramer Acetate (Copaxone®) Injection for the Treatment of Multiple Sclerosis

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie